RTX-224

N/A

Report date: 2022/03/14 17:17:03

Base Information

Drug NameRTX-224
Drug Alias NameRTX-224
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Erythrocyte therapy
Mechanisms of ActionNatural killer cells stimulantsCell replacementsT lymphocytes stimulants +[5] 
TargetsTumor necrosis factor ligand superfamily member 9Interleukin-12 receptor
Therapy Area/IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRubius Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRubius Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A